02256.HK_Providing professional financial news and data related to 02256.HK, committed to creating a comprehensive and efficient information access channel for users | NewTimeSpace

ABBISKO-B (02256.HK): Oral Pan-KRAS Inhibitor ABSK211 Cleared by FDA for Phase I Trial in KRAS-Altered Solid Tumours

Tags：

ABBISKO-B 02256.HK Clinical Trial

2026-07-13

Abbisko(02256.HK): Strategic Cooperation Reached with AstraZeneca to Advance Clinical Study of ABSK043 Combined with Tagrisso for NSCLC Treatment

Tags：

Abbisko 02256.HK

2026-07-02

ABBISKO-B(02256.HK): Positive Preliminary Phase II Data of ABSK061 Plus ABSK043 for FGFR2-Positive Advanced Gastric Cancer Released

Tags：

ABBISKO-B 02256.HK ASCO 2026

2026-06-26

ABBISKO-B(02256.HK): Enters Strategic Research Collaboration and License Agreement with Eli Lilly, Total Potential Deal Value Up to USD1.9 Billion

Tags：

ABBISKO-B 02256.HK strategic cooperation

2026-06-24

Heng Pharmaceutical-B (02256.HK) Presents Novel Combination Modelling Framework for ABSK-011 at PAGE Conference

Tags：

Heng Pharmaceutical-B 02256.HK

2026-06-04

ABBISKO-B (02256.HK) plans to issue in total 42.9 million shares by placement, with estimated net proceeds of HKD 517.3 million

Tags：

ABBISKO-B 02256.HK NewTimeSpace

2026-04-21

Scan QR Code

Download App